4-Fluoro-3-methylaniline | CAS:452-69-7

We serve 4-Fluoro-3-methylaniline CAS:452-69-7 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
4-Fluoro-3-methylaniline

Product Name: 4-Fluoro-3-methylaniline
Other Name: 2-Fluoro-5-aminotoluene;5-Amino-2-fluorotoluene;4-Fluoro-m-toluidine
CAS No: 452-69-7
MF: C7H8FN
MW: 125.14400
Density: 1,12 g/cm3
Boiling point: 85-86°C 9mm
Melting point: 35 °C
Flash point: 95°C
Refractive index: 1.5370
Vapor Pressure: 0.172mmHg at 25°C
UN Number: Not dangerous goods.
UN Proper Shipping Name: Not dangerous goods.
Transport hazard class: Not dangerous goods.
Packing group: Not dangerous goods.
 
Specification
Appearance: Light yellow transparent liquid
Purity: ≥98%
Water: ≤0.5%
 
Application: Organic intermediates, pharmaceutical intermediates.
Package: 25kg/drum, packed in plastic drum or plastic coated iron drum.
Storage: Store in cool place. Keep container tightly closed in a dry and well-ventilated place.



Contact us for information like 4-Fluoro-3-methylaniline chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,4-Fluoro-m-toluidine physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,5-Amino-2-fluorotoluene Use and application,5-Amino-2-fluorotoluene technical grade,usp/ep/jp grade.


Related News: Beijing will strengthen its monitoring of overseas drug market and collect global prices for imported medicines, Friday’s guideline said.(S,S)-2,8-Diazabicyclo[4,3,0]Nonane manufacturer Beijing will strengthen its monitoring of overseas drug market and collect global prices for imported medicines, Friday’s guideline said.4-Bromo-2-fluorobenzyl bromide supplier This part is mainly anti-tumor drugs, prostate drugs and certain hormone drugs.2-Bromo-3-Fluoro-4-Picoline vendor Rigosertib, in its intravenous formulation, is currently in Phase 3 clinical development for the treatment of higher-risk MDS.Rigosertib, in its intravenous formulation, is currently in Phase 3 clinical development for the treatment of higher-risk MDS.